Process for the treatment of humans suffering from undesired urotoxic
side effects caused by cytostatically active alkylating agents
    6.
    发明授权
    Process for the treatment of humans suffering from undesired urotoxic side effects caused by cytostatically active alkylating agents 失效
    用于治疗由细胞活性的活性烷化剂引起的不希望的尿毒性副作用的人的治疗方法

    公开(公告)号:US4220660A

    公开(公告)日:1980-09-02

    申请号:US967000

    申请日:1978-12-06

    申请人: Norbert Brock

    发明人: Norbert Brock

    CPC分类号: A61K31/675 A61K31/185

    摘要: The invention is related to a process for the treatment of humans suffering from undesired urotoxic side effects caused by cytostatically active alkylating agents administered to them against malign tumors, comprising administering a pharmacologically acceptable salt of a mercapto alkane sulfonic acid having the general formulaHS--alk--SO.sub.3 4to the human treated with the cytostatically active alkylating agent, in an amount ranging from 20% of the weight of the alkylating agent to the highest tolerated dosage of the salt of the mercapto alkane sulfonic acid, simultaneously or separately in combination with the alkylating agent.

    摘要翻译: 本发明涉及一种治疗患有由恶性肿瘤施用的细胞活性的烷化剂引起的不利的尿毒性副作用的人的方法,包括给予具有通式HS-alk的巯基烷烃磺酸的药学上可接受的盐 -SO34至用细胞活性的烷化剂处理的人,其量为烷基化剂重量的20%至巯基烷烃磺酸的盐的最高耐受剂量,同时或分开地与烷基化 代理商

    Process for the treatment of humans suffering from undesired urotoxic
side effects caused by cytostatically active alkylating agents
    7.
    发明授权
    Process for the treatment of humans suffering from undesired urotoxic side effects caused by cytostatically active alkylating agents 失效
    用于治疗由细胞活性的活性烷化剂引起的不希望的尿毒性副作用的人的治疗方法

    公开(公告)号:US4218471A

    公开(公告)日:1980-08-19

    申请号:US9625

    申请日:1979-02-06

    CPC分类号: A61K31/185 A61K31/675

    摘要: The invention is related to a process for the treatment of humans suffering from undesired urotoxic side effects caused by cytostatically active alkylating agents administered to them against malign tumors, comprising administering a pharmacologically acceptable salt of a dithiodi-(alkane sulfonic acid) having the general formula ##STR1## to the human treated with the cytostatically active alkylating agent, in an amount ranging from 20% of the weight of the alkylating agent to the highest tolerated dosage of the salt of the dithiodi-(alkane sulfonic acid), simultaneously or separately in combination with the alkylating agent.

    摘要翻译: 本发明涉及一种用于治疗患有由恶性肿瘤施用的细胞活性的烷化剂引起的不利的尿毒性副作用的人的方法,包括给予具有通式(II)的二硫代(烷烃磺酸)的药学上可接受的盐 对于用细胞活性活性烷化剂处理的人,其量为烷基化剂重量的20%至二硫代(烷烃磺酸)的盐的最高耐受剂量,同时或分开地 与烷基化剂组合。